Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

John W. Newcomer, Daniel (Dan) Haupt, Robert Fucetola, Angela K. Melson, Julie A. Schweiger, Benjamin P. Cooper, Gregg Selke

Research output: Contribution to journalArticle

464 Citations (Scopus)

Abstract

Background: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Methods: Modified oral glucose tolerance tests were performed in schizophrenic patients (n=48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n=31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Results: Significant time X treatment group interactions were detected for plasma glucose (F12,222=4.89, P12,171=2.10, P=.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated control subjects. Conclusion: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

Original languageEnglish (US)
Pages (from-to)337-345
Number of pages9
JournalArchives of General Psychiatry
Volume59
Issue number4
StatePublished - 2002
Externally publishedYes

Fingerprint

Antipsychotic Agents
Schizophrenia
Glucose
Adiposity
olanzapine
Risperidone
Fasting
Healthy Volunteers
Therapeutics
Clozapine
Glucose Tolerance Test
Hyperglycemia
Type 2 Diabetes Mellitus
Insulin Resistance
Age Groups
Population

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Newcomer, J. W., Haupt, D. D., Fucetola, R., Melson, A. K., Schweiger, J. A., Cooper, B. P., & Selke, G. (2002). Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry, 59(4), 337-345.

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. / Newcomer, John W.; Haupt, Daniel (Dan); Fucetola, Robert; Melson, Angela K.; Schweiger, Julie A.; Cooper, Benjamin P.; Selke, Gregg.

In: Archives of General Psychiatry, Vol. 59, No. 4, 2002, p. 337-345.

Research output: Contribution to journalArticle

Newcomer, JW, Haupt, DD, Fucetola, R, Melson, AK, Schweiger, JA, Cooper, BP & Selke, G 2002, 'Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia', Archives of General Psychiatry, vol. 59, no. 4, pp. 337-345.
Newcomer JW, Haupt DD, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Archives of General Psychiatry. 2002;59(4):337-345.
Newcomer, John W. ; Haupt, Daniel (Dan) ; Fucetola, Robert ; Melson, Angela K. ; Schweiger, Julie A. ; Cooper, Benjamin P. ; Selke, Gregg. / Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. In: Archives of General Psychiatry. 2002 ; Vol. 59, No. 4. pp. 337-345.
@article{f077b724f26140438b5ad074f4e1b73b,
title = "Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia",
abstract = "Background: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Methods: Modified oral glucose tolerance tests were performed in schizophrenic patients (n=48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n=31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Results: Significant time X treatment group interactions were detected for plasma glucose (F12,222=4.89, P12,171=2.10, P=.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated control subjects. Conclusion: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.",
author = "Newcomer, {John W.} and Haupt, {Daniel (Dan)} and Robert Fucetola and Melson, {Angela K.} and Schweiger, {Julie A.} and Cooper, {Benjamin P.} and Gregg Selke",
year = "2002",
language = "English (US)",
volume = "59",
pages = "337--345",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

AU - Newcomer, John W.

AU - Haupt, Daniel (Dan)

AU - Fucetola, Robert

AU - Melson, Angela K.

AU - Schweiger, Julie A.

AU - Cooper, Benjamin P.

AU - Selke, Gregg

PY - 2002

Y1 - 2002

N2 - Background: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Methods: Modified oral glucose tolerance tests were performed in schizophrenic patients (n=48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n=31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Results: Significant time X treatment group interactions were detected for plasma glucose (F12,222=4.89, P12,171=2.10, P=.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated control subjects. Conclusion: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

AB - Background: Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population. Glucoregulatory abnormalities have also been associated with the use of antipsychotic medications themselves. While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity. Methods: Modified oral glucose tolerance tests were performed in schizophrenic patients (n=48) receiving clozapine, olanzapine, risperidone, or typical antipsychotics, and untreated healthy control subjects (n=31), excluding subjects with diabetes and matching groups for adiposity and age. Plasma was sampled at 0 (fasting), 15, 45, and 75 minutes after glucose load. Results: Significant time X treatment group interactions were detected for plasma glucose (F12,222=4.89, P12,171=2.10, P=.02) levels, with significant effects of treatment group on plasma glucose level at all time points. Olanzapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at all time points, in comparison with patients receiving typical antipsychotics as well as untreated healthy control subjects. Clozapine-treated patients had significant (1.0-1.5 SDs) glucose elevations at fasting and 75 minutes after load, again in comparison with patients receiving typical antipsychotics and untreated control subjects. Risperidone-treated patients had elevations in fasting and postload glucose levels, but only in comparison with untreated healthy control subjects. No differences in mean plasma glucose level were detected when comparing risperidone-treated vs typical antipsychotic-treated patients and when comparing typical antipsychotic-treated patients vs untreated control subjects. Conclusion: Antipsychotic treatment of nondiabetic patients with schizophrenia can be associated with adverse effects on glucose regulation, which can vary in severity independent of adiposity and potentially increase long-term cardiovascular risk.

UR - http://www.scopus.com/inward/record.url?scp=0036215480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036215480&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 337

EP - 345

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 4

ER -